McClure Jesse J, Inks Elizabeth S, Zhang Cheng, Peterson Yuri K, Li Jiaying, Chundru Kalyan, Lee Bradley, Buchanan Ashley, Miao Shiqin, Chou C James
Medical University of South Carolina , College of Pharmacy, Charleston, South Carolina, United States.
China Agricultural University , Department of Applied Chemistry, Beijing, China.
ACS Chem Biol. 2017 Jun 16;12(6):1644-1655. doi: 10.1021/acschembio.7b00321. Epub 2017 May 4.
The acetylation status of lysine residues on histone proteins has long been attributed to a balance struck between the catalytic activity of histone acetyl transferases and histone deacetylases (HDAC). HDACs were identified as the sole removers of acetyl post-translational modifications (PTM) of histone lysine residues. Studies into the biological role of HDACs have also elucidated their role as removers of acetyl PTMs from lysine residues of nonhistone proteins. These findings, coupled with high-resolution mass spectrometry studies that revealed the presence of acyl-group PTMs on lysine residues of nonhistone proteins, brought forth the possibility of HDACs acting as removers of both acyl- and acetyl-based PTMs. We posited that HDACs fulfill this dual role and sought to investigate their specificity. Utilizing a fluorescence-based assay and biologically relevant acyl-substrates, the selectivities of zinc-dependent HDACs toward these acyl-based PTMs were identified. These findings were further validated using cellular models and molecular biology techniques. As a proof of principal, an HDAC3 selective inhibitor was designed using HDAC3's substrate preference. This resulting inhibitor demonstrates nanomolar activity and >30 fold selectivity toward HDAC3 compared to the other class I HDACs. This inhibitor is capable of increasing p65 acetylation, attenuating NF-κB activation, and thereby preventing downstream nitric oxide signaling. Additionally, this selective HDAC3 inhibition allows for control of HMGB-1 secretion from activated macrophages without altering the acetylation status of histones or tubulin.
长期以来,组蛋白上赖氨酸残基的乙酰化状态一直被认为是组蛋白乙酰转移酶和组蛋白去乙酰化酶(HDAC)催化活性之间达到的一种平衡。HDAC被确定为组蛋白赖氨酸残基乙酰化翻译后修饰(PTM)的唯一去除者。对HDAC生物学作用的研究也阐明了它们作为非组蛋白赖氨酸残基乙酰化PTM去除者的作用。这些发现,再加上高分辨率质谱研究揭示了非组蛋白赖氨酸残基上存在酰基PTM,提出了HDAC作为酰基和乙酰基PTM去除者的可能性。我们推测HDAC发挥这种双重作用,并试图研究它们的特异性。利用基于荧光的检测方法和生物学相关的酰基底物,确定了锌依赖性HDAC对这些基于酰基的PTM的选择性。这些发现通过细胞模型和分子生物学技术得到了进一步验证。作为原理验证,利用HDAC3的底物偏好设计了一种HDAC3选择性抑制剂。与其他I类HDAC相比,这种产生的抑制剂表现出纳摩尔活性和对HDAC3大于30倍的选择性。这种抑制剂能够增加p65乙酰化,减弱NF-κB激活,从而阻止下游一氧化氮信号传导。此外,这种选择性HDAC3抑制能够控制活化巨噬细胞中HMGB-1的分泌,而不改变组蛋白或微管蛋白的乙酰化状态。